Soliton Reports Fourth Quarter and Full Year 2019 Results.

HOUSTON: Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today reported financial results for the fourth quarter and full year ended December 31, 2019.

Recent Company Highlights:

Completed pivotal cellulite clinical trial with all required patients successfully treated across four clinical sites and initiated patient follow-up visits

Completed 12-week keloid proof-of-concept clinical trial with positive results

Submitted 510(k) for the updates to the Gen 2 device for the tattoo removal indication

Entered into 3-year development agreement with Emphysys for design and engineering services related to the acoustical shockwave therapy

Significant 2019 Company Milestones:

Completed initial public offering and listing on NASDAQ on February 19, 2019

Received FDA Clearance of initial device on May 24, 2019, clearing the device for use as an accessory to a 1064 Q-switch laser for tattoo removal

Honored with the "Best in Session" award by the American Society for Laser Medicine & Surgery, the world's largest scientific organization in the field of medical laser applications

Added to the Russell 2000 and 3000 Indexes in June 2019

Demonstrated in proof-of-concept trial the ability of technology to deliver "acoustic subcision," a key step for the potential treatment using the device, if approved, of cellulite dimples and ridges

Initiated a full, four-site pivotal clinical trial for the treatment of cellulite, with results expected in Q1 2020

Increased the size of the patent portfolio with an additional 31 patents filed and 17 patents granted

Closed two private placements for a total of $15.95 million in gross proceeds

Dr. Chris Capelli, Soliton's President, CEO and co-founder, commented, "We achieved significant clinical and corporate milestones in 2019 that we believe will prove fundamental to Soliton's future success. The completion of Company's initial public offering last February highlights the long-term opportunity for our investors. In conjunction with an FDA clearance of our Rapid Acoustic Pulse ("RAP") device for tattoo removal in May, we look forward to leveraging the platform technology for the potential treatment, if approved, of cellulite and keloid scars. We believe the positive results from our 12-week keloid proof-of-concept study further validate our growth...